EA201500363A1 - Человеческие анти-vegfr-2/kdr-антитела - Google Patents

Человеческие анти-vegfr-2/kdr-антитела

Info

Publication number
EA201500363A1
EA201500363A1 EA201500363A EA201500363A EA201500363A1 EA 201500363 A1 EA201500363 A1 EA 201500363A1 EA 201500363 A EA201500363 A EA 201500363A EA 201500363 A EA201500363 A EA 201500363A EA 201500363 A1 EA201500363 A1 EA 201500363A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
vegfr
kdr
human anti
monotherapy
Prior art date
Application number
EA201500363A
Other languages
English (en)
Other versions
EA032679B1 (ru
EA201500363A8 (ru
Inventor
Чжэньпин Чжу
Дан Лу
Original Assignee
Кадмон Корпорейшн, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадмон Корпорейшн, Ллк filed Critical Кадмон Корпорейшн, Ллк
Publication of EA201500363A1 publication Critical patent/EA201500363A1/ru
Publication of EA201500363A8 publication Critical patent/EA201500363A8/ru
Publication of EA032679B1 publication Critical patent/EA032679B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к антителам, которые связываются с VEGFR-2. Антитела используются для лечения неопластических заболеваний, гиперпролиферативных процессов, ангиогенных нарушений и могут применяться в качестве монотерапии или в сочетании с другими агентами.
EA201500363A 2012-10-05 2013-10-07 Человеческие анти-vegfr-2/kdr-антитела EA032679B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710420P 2012-10-05 2012-10-05
PCT/US2013/063754 WO2014055998A1 (en) 2012-10-05 2013-10-07 Human anti-vegfr-2/kdr antibodies

Publications (3)

Publication Number Publication Date
EA201500363A1 true EA201500363A1 (ru) 2015-11-30
EA201500363A8 EA201500363A8 (ru) 2016-04-29
EA032679B1 EA032679B1 (ru) 2019-07-31

Family

ID=50435514

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201500363A EA032679B1 (ru) 2012-10-05 2013-10-07 Человеческие анти-vegfr-2/kdr-антитела
EA201990403A EA039595B1 (ru) 2012-10-05 2013-10-07 Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990403A EA039595B1 (ru) 2012-10-05 2013-10-07 Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела

Country Status (9)

Country Link
US (2) US10023640B2 (ru)
EP (2) EP2903647B1 (ru)
JP (1) JP6449772B2 (ru)
CN (3) CN116003600A (ru)
CA (1) CA2926386C (ru)
EA (2) EA032679B1 (ru)
ES (2) ES2966030T3 (ru)
PL (1) PL3685855T3 (ru)
WO (1) WO2014055998A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204423A4 (en) 2014-10-07 2018-03-28 Kadmon Corporation, LLC Human anti-vegfr-2/kdr antibodies
AU2016249991B2 (en) * 2015-04-14 2021-03-25 Academia Sinica Anti-VEGFR2 human antibody for anti-angiogenic and targeted cancer therapy
TW201718641A (zh) * 2015-06-30 2017-06-01 偉東 姜 抗血管內皮生長因子受體２（ｖｅｇｆｒ２）抗體
KR101896882B1 (ko) * 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
US20170233480A1 (en) * 2015-12-31 2017-08-17 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CN113480653B (zh) * 2021-08-06 2022-05-06 朱有建 一种含有γδT细胞的药物组合物在治疗癌症中的用途
KR20230109853A (ko) * 2022-01-14 2023-07-21 주식회사 파멥신 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
PT1397364E (pt) 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
EP1916001B1 (en) * 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
ES2291664T3 (es) 2002-09-17 2008-03-01 Eli Lilly And Company Derivados de pirazolopiridina como inhibidores de la transduccion de señales de tgf beta para el tratamiento del cancer.
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
AU2003291642A1 (en) 2002-11-22 2004-06-18 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US7405299B2 (en) 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
WO2007079218A2 (en) 2005-12-30 2007-07-12 Dyax Corp. Metalloproteinase binding proteins
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
AU2009221915A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
AU2010222848A1 (en) * 2009-03-09 2011-10-20 Surface Logix, Inc. Rho kinase inhibitors
US8128932B2 (en) * 2009-08-17 2012-03-06 Shanghai Aosaiersi Biotech Co., Ltd. Anti-VEGFR monoclonal antibody, method of making and uses thereof
CN101863980B (zh) * 2009-12-31 2013-05-08 中国药科大学 全人源抗血管内皮细胞生长因子受体2单链抗体
WO2012004631A2 (en) 2010-07-07 2012-01-12 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)

Also Published As

Publication number Publication date
US10023640B2 (en) 2018-07-17
EP2903647A4 (en) 2016-08-17
PL3685855T3 (pl) 2024-04-08
EA032679B1 (ru) 2019-07-31
EA039595B1 (ru) 2022-02-15
EP3685855B1 (en) 2023-11-22
JP2015533126A (ja) 2015-11-19
ES2781974T3 (es) 2020-09-09
ES2966030T3 (es) 2024-04-18
CN105007939B (zh) 2018-10-19
CN116003600A (zh) 2023-04-25
EA201990403A1 (ru) 2019-07-31
CN109160950A (zh) 2019-01-08
WO2014055998A1 (en) 2014-04-10
JP6449772B2 (ja) 2019-01-09
CN105007939A (zh) 2015-10-28
US10364291B2 (en) 2019-07-30
US20150284464A1 (en) 2015-10-08
EP3685855C0 (en) 2023-11-22
CA2926386C (en) 2021-11-09
EP2903647B1 (en) 2020-01-01
EP2903647A1 (en) 2015-08-12
EP3685855A1 (en) 2020-07-29
CN109160950B (zh) 2022-10-04
US20180346579A1 (en) 2018-12-06
EA201500363A8 (ru) 2016-04-29
CA2926386A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
EA201791093A1 (ru) Антитела к cd47, способы и применение
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
EA201500363A8 (ru) Человеческие анти-vegfr-2/kdr-антитела
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
PH12015501360A1 (en) Bmp-6 antibodies
UA118674C2 (uk) Антитіло до igf-1r з елімінованою здатністю зв'язуватися з fcrn та його застосування для лікування судинних захворювань очей
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний